Full-Time

Director – Medical Science Liaison Plastics & Regenerative Medicine

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$160.5k - $305k/yr

+ Long-term incentive programs

Miami, FL, USA

Remote

Willing to travel approximately 50-60% of the time to cover the designated territory.

PharmD, PhD, MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Advanced degree in health sciences or clinical discipline required. Preferred: Doctorate level degree (i.e. Pharm D, MD/DO, PhD).
  • A minimum of 5 years clinical, scientific/research, or pharma industry related experience or equivalent with at least 2 of those years as an MSL.
  • Prior line management experience of a field-based MSL team strongly preferred; experience as a player-coach or working manager is a distinct advantage.
  • Excellent written and spoken communication and presentation skills (local language and English preferred).
  • Proven success in managing multiple projects simultaneously.
  • Proven ability to work collaboratively cross functionally.
  • Experience managing and resolving challenging personnel issues.
  • Ability to travel regularly (approximately 50–60%) to support both direct territory KOL engagement and team co-rides/coaching activities across the 6-person MSL team's geography.
  • Experience with OR/surgical suite environments and familiarity with credentialing and OR certification processes strongly preferred.
  • Demonstrated ability to manage operational and administrative responsibilities (e.g., expense approvals, vendor contracting, tool and resource management) alongside active field engagement duties.
Responsibilities
  • Ensuring development and implementation of scientific interaction plans for the Plastics & Regenerative Medicine therapeutic area for both on-market products and pipeline products in a timely manner. Provides field scientific support across the lifecycle of a product including both planning and execution by the MSL team and conducts ongoing analysis of clinical and market trends to develop key supporting strategies to meet business objectives.
  • Proactively participate in Brand Team Meetings ensuring the field medical voice is present to help with plans, communication, monitoring and reporting of MSL metrics and bringing MSL data points and observations into the discussion to help with development of insights for action plans. Ensure MSLs are fully utilizing technology (e.g., CRM, virtual engagement tools, P2P platforms) according to requirements and guidance provided.
  • Proactively analyzes business needs working in conjunction with the Infield team and the Brand Team (if applicable) to identify opportunities where MSL function enhances business results.
  • Manage performance of the 6-person MSL team to ensure activities are appropriately aligned to Brand and Medical strategies and plans, while ensuring compliance with all national, local guidelines, and company policies and procedures.
  • Provide expertise and feedback to coach MSLs in their most important activities (including engagement planning, ensuring that EE/HCP interactions are of high quality in scientific content and interaction approach (Challenger) and scientific storytelling, clinical study engagement activities, responding to medical information enquiries, capturing and reporting of data points and observations, coordination of activities with other in field teams). This includes setting of objectives and regular performance reviews.
  • Monitor the overall MSL team activities/workload and plan appropriately for resource needs-based product lifecycle and therapeutic area needs.
  • Maintains proactive and appropriate communication within the broader affiliate Medical Team and Brand Team for therapeutic area/product as it relates to MSL activities/outcomes that support the achievement of business objectives.
  • Conduct regular field co-rides and 1:1s with all direct reports, using an appropriate combination of direction, support, coaching, and constructive challenge to enable direct reports to fulfill their role requirements, achieve their goals, and continually develop. Field co-rides should include direct observation of scientific exchanges, OR-based interactions, and KOL engagement visits where relevant.
  • Ensure coordination between MSLs and other members of the in-field teams to ensure integration of medical activities with in- field plans.
  • Drive recruitment activities for new or replacement positions; ensure on-boarding and training of new MSLs within the therapeutic area team.
  • Ensure appropriate scientific support and training is provided to the internal stakeholders (i.e. sales training).
  • In-field team leaders regularly participate in team meetings and contributing to development of plans and monitoring of progress on such plans (mainly related to Field Medical role).
  • Highlighting FM value to the business by communicating MSL achievements and metrics with appropriate affiliate roles.
  • Drive field readiness across the team, ensuring MSLs have the scientific training, tools, and resources they need to excel in their roles, including management and maintenance of Operating Room (OR) certifications for team members. Proactively identify gaps and escalate to appropriate responsible parties to ensure rapid resolution. Oversee operational logistics including MSL tool management and vendor contracting as required.
  • Keeping up to date in therapeutic area, scientific narratives and main study data (at appropriate level) to ensure ability to coach MSL on scientific content of presentations.
  • Responsible for overall financial and administrative management for the MSL team, including timely review and approval of MSL expense reports to ensure compliance with company policy. Manages day-to-day administrative team duties and operational logistics to ensure smooth team functioning.
  • Serve as the primary MSL for a small, designated territory (exact geography TBD), maintaining active KOL and HCP engagement in that region to provide direct scientific value, stay current with evolving market dynamics, and model best-in-class field engagement practices for the broader team.
Desired Qualifications
  • Doctorate level degree (i.e. Pharm D, MD/DO, PhD) preferred.
  • Prior line management experience of a field-based MSL team strongly preferred; experience as a player-coach or working manager is a distinct advantage.
  • Experience managing and resolving challenging personnel issues.
  • Experience with OR/surgical suite environments and familiarity with credentialing and OR certification processes strongly preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.